Evaluation of Atorvastatin Safety on Liver Function Tests, a Prospective Study
Novelty in Biomedicine,
Vol. 3 No. 3 (2015),
22 Tir 2015
,
Page 99-102
https://doi.org/10.22037/nbm.v3i3.7657
Abstract
Background: Although lipid lowering agents as statins are used frequently in hyperlipidemic patients as well as patients with cardiac disease, they could have major hepatic side effects, the aim of this study is to evaluate the safety of statins mainly atorvastatin on liver as estimated by liver aminotransferase assay.Materials and Methods: Patients with indication of atorvastatin were included the study. As a before and after study all the patients underwent serum level measurement of aminotransferases at the beginning and after three month of taking the drug.
Results and Conclusion: HMG-COA reductase as atorvastatin should be safe in different doses 20,40 and 80 mg in patient with hyperlipidemia with and without cardiac disease without significant hepatotoxicity.
- Keywords
- HMGG-COA reductase
- hepatotoxicity
- statins
- atorvastatin
How to Cite
References
Justin L. The Increasing Incidence of Coronary Artery Disease and Cardiovascular Risk Factors among a Southwest Native American Tribe. ARCH INTERN MED. 2002;162-5.
Parra JL, Reddy KR. Hepatotoxicity of hypolipidemic drugs. Clin Liver Dis. 2003;7:415-33.
Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review.
Cder-phrma. AASLD Conference 2000: clinical white paper on drug-induced hepatotoxicity.
Hardisty JF, Brix AE. Comparative hepatic toxicity: prechronic/ chronic liver toxicity in rodents. Toxicol Pathol. 2005;33(1):35-40.
Navarro VJ, Senior JR. Drug-related Hepatotoxicity. N Engl J Med. 2006;354:731-9
Cohen DE, Anania FA, Chalasani N. An assessment of statin safety by hepatologists. Am J Cardiol. 2006;97:77-81.
Hou R, Goldberg AC. Lowering low-density lipoprotein cholesterol: statins, ezetimibe, bile acid sequestrants, and combinations: comparative efficacy and safety. Endocrinol Metab Clin North Am. 2009;38:79-97.
Pugh AJ, Barve AJ, Falkner K, et al. Drug-induced hepatotoxicity or drug-induced liver injury. Clin Liver Dis. 2009;13:277-94.
Wilson JP, Omar MA و Cox TS. Rhabdomyolysis and HMG-CoA reductase inhibitors. Ann Pharmacother. 2001;35(9):1096-107.
Talbert RL. Safety issues with statin therapy. Journal of the American Pharmacists Association: JAPhA. 2006;479(2):46-9.
Nakad A, Bataille L, Hamoir V, Sempoux C, Horsman Y. Atorvastatin-induced acute hepatitis with absence of cross-toxicity with simvastatin. Lancet 1999;353(9166):1763–4.
De Castro ML, Hermo JA, Baz A, de Luaces C, Perez R, Clofent J. Acute cholestatic hepatitis after atorvastatin reintroduction. Gastroenterologia y Hepatologia. 2006;29(1):21–4.
Gershovich OE, Lyman AE. Liver function test abnormalities and pruritis in a patient treated with atorvastatin: case report and review of the literature. Pharmacotherapy. 2004;24(1):150–4.
Jimenez-Alonso J, Osorio JM, Guierrez-Cabello F, de la Osa AL, Leon L, Garcia JDM. Atorvastatininduced cholestatic hepatitis in a young woman with systemic lupus erythematosus. Archives of Internal Medicine. 1999;159(15):1811–2.
Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors, Arterioscler Thromb Vasc Biol. 2001;21:1712-19.
Jones PH, Davidson MH, Stein EA, Bays HE, Miller E, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol. 2003;92:152.
Aviram M, Dankner G, Cogan U, et al. Lovastatin inhibits LDL oxidation and alters its fluidity and uptake by macrophages: in vitro and in vivo studies. Metabolism. 1992;41:229–35.
Chen L, Haught WH, Yang B, Saldeen TG, Parathasarathy S, et al. Preservation of endogenous antioxidant activity and inhibition of lipid peroxidation as common mechanisms of antiatherosclerotic effects of vitamin E, lovastatin and amlodipine. J Am Coll Cardiol. 1997;30:569–75.
Kimura M, Kurose I, Russell J,Granger DN. Effects of fluvastatin on leukocyteendothelial cell adhesion in hypercholesterolemic rats. Arterioscler Thromb Vasc Biol. 1997;17;11521–6.
Lehr HA, Seemuller J, Hubner C, Menger MD, Messmer K. Oxidized LDL-induced leukocyte/endothelium interaction in vivo involves the receptor for platelet activating factor. Arterioscler Thromb. 1993;13:1013–18.
Saito Y, Yoshida S, Nakaya N, Hata Y, Goto Y. Comparison between morning and evening doses of simvastatin in hyperlipidemic subjects. A double-blind comparative study. Arterioscler Thromb. 1991;11:816.
Bader T. Liver tests are irrelevant when prescribing statins. Lancet. 2010;376:1882-3.
Björnsson ES, Bergmann OM, Björnsson HK, Kvaran RB, Olafsson S. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology. 2013;144:1419-25.
Björnsson E, Jacobsen E, Kalaitzakis. Hepatotoxicity associated with statins: Reports or idiosyncratic liver injury post-marketing. J Hepatol. 2012;56:374-80.
El-Serag HB, Johnson ML, Hachem C, Morgano RO. Statins are associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients with diabetes. Gastroenterology. 2009;136:1601-8.
Lucena MI, Andrade RJ, Kaplowitz N, García-Cortés M, Fernández MC, RomeroGómez M, et al. Phenotypic characterization of idiosyncratic drug- induced liver Injury: The influence of age and sex. Hepatology. 2009;49:2001-9.
Andrade RJ, Lucena MI, Fernández MC, Peláez G, Pachkoria K, García-Ruiz E, et al. Drug-induced liver injury: An analysis of 461 incidences submitted to the Spanish Registry over a 10-year period. Gastroenterology. 2005;129:512-21.
FDA Guidance for Industry, Drug-induced liver injury: Premarketing Clinical Evaluation (Issued July2009).
Chalasani N. Statins and hepatotoxicity: focus on patients with fatter liver.Hepatology. 2005;41:690-5.
Cueto R, Valdivielso P, Lucena MI, García-Arias C, Andrade RJ, González-Santos P.Statins: Hepatic disease and hepatotoxicity risk. Open Gastroenterol J. 2008;2:18-23.
Russo MW, Scobet M, Bonkovsky. Drug-induced liver injury associated with Statins.Semin Liver Dis 2009;29:412-22.analysis. BMJ. 2003;326:1423.
Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol. 2006;97(8A):52C-60C
- Abstract Viewed: 928 times
- PDF Downloaded: 556 times